Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / CL A
-
Number of holders
-
207
-
Total 13F shares, excl. options
-
23,190,263
-
Shares change
-
+561,579
-
Total reported value, excl. options
-
$3,622,845,015
-
Value change
-
+$93,584,154
-
Put/Call ratio
-
75%
-
Number of buys
-
111
-
Number of sells
-
-103
-
Price
-
$156.02
Significant Holders of REATA PHARMACEUTICALS INC - CL A (RETA) as of Q2 2020
277 filings reported holding RETA - REATA PHARMACEUTICALS INC - CL A as of Q2 2020.
REATA PHARMACEUTICALS INC - CL A (RETA) has 207 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23,190,263 shares
.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (3,741,699 shares), CPMG Inc (3,063,567 shares), VANGUARD GROUP INC (2,203,551 shares), BlackRock Inc. (1,606,730 shares), FRANKLIN RESOURCES INC (1,333,081 shares), PRICE T ROWE ASSOCIATES INC /MD/ (929,322 shares), FMR LLC (866,848 shares), Duquesne Family Office LLC (532,878 shares), Cormorant Asset Management, LP (400,000 shares), and STATE STREET CORP (361,277 shares).
This table shows the top 207 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.